Table 2.
Meta-analysis of the efficacy of MSC in the therapy of patients with lupus nephritis (RCT).
| Indicators | Time point | Studies | Q test | Model | OR/WMD | P |
|---|---|---|---|---|---|---|
| Number | P value | Selected | (95% CI) | |||
| Proteinuria | 2 months | 1 | — | Fixed | -1.74 (-5.00, 1.52) | 0.30 |
| 3 months | 1 | — | Fixed | -0.92 (-1.05, -0.79) | <0.00001 | |
| 6 months | 2 | 0.84 | Fixed | -2.00 (-3.81, -0.19) | 0.03 | |
| 12 months | 2 | <0.00001 | Random | -0.46 (-1.37, 0.45) | 0.33 | |
|
| ||||||
| Scr | 3 months | 1 | — | Fixed | -2.52 (-8.53, 3.49) | 0.41 |
| 6 months | 1 | — | Fixed | 3.92 (-8.55, 16.39) | 0.54 | |
| 12 months | 2 | 0.05 | Random | -0.74 (-14.04, 12.56) | 0.91 | |
|
| ||||||
| Serum albumin | 3 months | 1 | — | Fixed | 7.85 (5.93, 9.77) | <0.00001 |
| 12 months | 2 | 0.15 | Fixed | 0.94 (-0.53, 2.40) | 0.21 | |
|
| ||||||
| C3 | 3 months | 1 | — | Fixed | 0.28 (0.16, 0.40) | <0.00001 |
| 12 months | 2 | 0.02 | Random | 0.36 (-0.08, 0.79) | 0.11 | |
|
| ||||||
| C4 | 3 months | 1 | — | Fixed | -0.01 (-0.04, 0.02) | 0.46 |
| 12 months | 2 | 0.31 | Fixed | -0.01 (-0.03, 0.01) | 0.39 | |
|
| ||||||
| SLEDAI | 2 months | 1 | — | Fixed | -6.25 (-9.04, -3.46) | <0.0001 |
| 3 months | 1 | — | Fixed | -0.89 (-2.19, 0.41) | 0.18 | |
| 6 months | 1 | — | Fixed | -4.25 (-6.78, -1.72) | 0.001 | |
| 12 months | 2 | 0.004 | Random | -1.00 (-3.13, 1.14) | 0.36 | |
|
| ||||||
| Adverse events | — | 2 | 0.66 | Fixed | 0.26 (0.07, 0.89) | 0.03 |